MYO — Myomo, Inc.

Myomo Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $10.1 million, a 10% increase year-over-year, driven by a higher number of revenue units.
• Units Delivered: 186 MyoPro units, up 16% from the prior year.
• Average Selling Price (ASP): Approximately $54,300, a 5% decrease year-over-year but normalized for accounting changes, an increase of 3%.
• Gross Margin: 63.8%, down from 75.4% in the prior year, impacted by higher costs and changes in inventory absorption.
• Operating Loss: $3.5 million, compared to a $1 million loss in the prior year.
• Net Loss: $3.7 million, or $0.09 per share, compared to a $1 million loss, or $0.03 per share, in the prior year.
• Cash Position: $12.6 million as of September 30, 2025, with a cash burn of $2.9 million for the quarter.

2. Strategic Updates and Business Highlights

• International Growth: Record international revenue of $1.8 million, primarily from Germany, which has a well-established network of O&P partners.
• MyoConnect Program: A new initiative aimed at generating high-quality patient referrals through clinical practitioners, which is showing early traction.
• O&P Channel Expansion: Revenue from the O&P channel reached $900,000, up 154% year-over-year, indicating strong growth potential.
• Insurance Coverage: Increased authorizations from Medicare Advantage plans and new contracts signed, bringing total covered lives to 35 million.

3. Forward Guidance and Outlook

• 2025 Revenue Guidance: Reiterated guidance of $40 million to $42 million, representing over 23% growth from the previous year.
• 2026 Focus: Plans to diversify revenue streams away from advertising-driven sales, emphasizing MyoConnect and O&P channel growth.

4. Challenges and Points of Concern

• Medicare Advantage Revenue Decline: Revenue from Medicare Advantage decreased by 18% year-over-year due to high pre-authorization denial rates.
• Operating Expenses: Total operating expenses increased by 26% year-over-year, driven by higher payroll and advertising costs.
• Backlog Reduction: Backlog decreased by 34% year-over-year, indicating challenges in converting authorizations to revenue.
• Gross Margin Pressure: Significant decline in gross margin due to increased costs and operational inefficiencies.

5. Notable Q&A Insights

• O&P Channel Metrics: Approximately 30 units shipped to the O&P channel in Q3, indicating early-stage growth.
• Customer Acquisition Costs: The new Head of Marketing is reviewing advertising effectiveness to improve lead generation and reduce costs.
• Pipeline Growth: The pipeline increased by 32% year-over-year, with expectations for continued growth through the MyoConnect program.
• Debt Strategy: Management expressed confidence in their ability to repay the new $17.5 million term loan, emphasizing a focus on revenue growth and cost management to achieve breakeven.

Overall, while Myomo reported strong revenue growth and strategic advancements, challenges remain in operating expenses, backlog management, and Medicare Advantage revenue, which could impact future performance.